Shanghai Pharmaceuticals Holding (601607.SH): Tofacitinib Citrate Extended-Release Tablets Approved for Production.

Shanghai Pharmaceuticals Holding (601607.SH) announced that recently, its subsidiary Shanghai Pharmaceutical Western Medicine Co., Ltd. (referred to as "Shanghai Pharmaceutical Western Medicine") has received the "Drug Registration Certificate" (Certificate Number: 2025S03257) issued by the National Medical Products Administration for its delayed-release tablets of Tofacitinib citrate. The drug has been approved for production. Tofacitinib citrate delayed-release tablets are used to treat rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Originally developed by Pfizer, it was first launched in the United States in 2016. In January 2024, Shanghai Pharmaceutical Western Medicine submitted an application for registration and listing of the drug to the National Medical Products Administration, which was accepted. As of the announcement date, the company has invested approximately RMB 19.4192 million in research and development expenses for this drug.